,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,179,1,1,,460264,2789,Inactive,,,,,NCI AIDS Antiviral Assay,Confirmatory,,
1,330,1,1,,460264,2789,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P388 Leukemia (intraperitoneal) in CD2F1 (CDF1) mice,Other,,
2,1471,2,1,,50113062,2789,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
3,1490,2,1,,50113062,2789,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
4,1688,1,1,,50113062,2789,Inactive,90903231.0,3064.0,,Potency,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP),Confirmatory,,
5,1766,1,1,,50113062,2789,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
6,1766,1,1,,50113062,2789,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
7,1768,1,1,,50113062,2789,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
8,1768,1,1,,50113062,2789,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
9,2528,1,2,,50113062,2789,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
10,2546,1,1,,50113062,2789,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
11,2551,1,1,,50113062,2789,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
12,2662,2,1,,50113062,2789,Inactive,56550039.0,4297.0,,Potency,qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction,Confirmatory,,
13,27167,3,4,,103266846,2789,Unspecified,,,,,Delta logD (logD6.5 - logD7.4),Other,10891117.0,
14,28681,3,4,,103266846,2789,Unspecified,,,,,Partition coefficient (logD6.5),Other,10891117.0,
15,29363,3,3,,103266846,2789,Inconclusive,,,,,Dissociation constant (pKa),Other,10891117.0,
16,29811,4,3,,103266846,2789,Unspecified,,,,,Oral bioavailability in human,Other,10891117.0,
17,113273,6,2,,103266846,2789,Unspecified,,,,,Antiaggressive anxiolytic activity in the electroshock-induced fighting test in mice (po); Range (1.03-4.7;),Other,1977910.0,
18,113677,6,2,,103266846,2789,Unspecified,,,,,Effect on hexobarbital induced sleep was determined in hexobarbital potentiation test; Range (9.6-17.1),Other,1977910.0,
19,114461,6,2,,103266846,2789,Unspecified,,,,,Ataxic activity in mice by rotarod test; Range (2.2-6.4),Other,1977910.0,
20,135326,5,2,,103266846,2789,Unspecified,,,,,BBB penetration classification,Other,10841799.0,
21,227701,3,3,,103266846,2789,Unspecified,,,,,Anticonvulsant activity; NC denotes that compound is not classified,Other,12873507.0,
22,235587,3,3,,103266846,2789,Unspecified,,,,,Ratio of ED50 (hexobarbital) to that of ED50 (fighting),Other,1977910.0,
23,235588,3,3,,103266846,2789,Unspecified,,,,,Ratio of ED50 (rotarod) to that of ED50 (fighting),Other,1977910.0,
24,256135,6,1,,103266846,2789,Unspecified,,,,,Effect on GABA level in rat whole brain concentration after 2 hr post-treatment at a dose of 100 mg/Kg when given i.p.; Control 48.4,Other,16190747.0,
25,256146,6,1,,103266846,2789,Unspecified,,,,,Effect on GABA level in rat whole brain concentration after 7 days post-treatment at a dose of 30 mg/Kg when given orally; Control 50.5,Other,16190747.0,
26,489300,3,5,,103266846,2789,Unspecified,,,,,"Increase in GABA level in Wistar rat midbrain assessed per mg of tissue at 30 mg/kg, ip after 2 hrs",Other,20558061.0,
27,489302,3,5,,103266846,2789,Unspecified,,,,,"Increase in GABA level in Wistar rat medulla oblangata assessed per mg of tissue at 30 mg/kg, ip after 2 hrs",Other,20558061.0,
28,489304,3,5,,103266846,2789,Unspecified,,,,,"Increase in GABA level in Wistar rat cerebellum assessed per mg of tissue at 30 mg/kg, ip after 2 hrs",Other,20558061.0,
29,492961,1,1,,50113062,2789,Inactive,72386991.0,3656265.0,,Potency,qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase: hit validation,Confirmatory,,
30,504327,1,1,,50113062,2789,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
31,504332,1,1,,50113062,2789,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
32,504749,1,3,,50113062,2789,Unspecified,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
33,504749,1,3,1.0,50113062,2789,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
34,504749,1,3,2.0,50113062,2789,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
35,504749,1,3,3.0,50113062,2789,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
36,504749,1,3,4.0,50113062,2789,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
37,504749,1,3,5.0,50113062,2789,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
38,504749,1,3,6.0,50113062,2789,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
39,504749,1,3,7.0,50113062,2789,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
40,504749,1,3,8.0,50113062,2789,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
41,504749,1,3,9.0,50113062,2789,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
42,504749,1,3,10.0,50113062,2789,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
43,504749,1,3,11.0,50113062,2789,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
44,504749,1,3,12.0,50113062,2789,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
45,504749,1,3,13.0,50113062,2789,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
46,504749,1,3,14.0,50113062,2789,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
47,504749,1,3,15.0,50113062,2789,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
48,504749,1,3,16.0,50113062,2789,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
49,504749,1,3,17.0,50113062,2789,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
50,504749,1,3,18.0,50113062,2789,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
51,504749,1,3,19.0,50113062,2789,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
52,504749,1,3,20.0,50113062,2789,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
53,504749,1,3,21.0,50113062,2789,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
54,504749,1,3,22.0,50113062,2789,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
55,504749,1,3,23.0,50113062,2789,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
56,504749,1,3,24.0,50113062,2789,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
57,504749,1,3,25.0,50113062,2789,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
58,504749,1,3,26.0,50113062,2789,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
59,504749,1,3,27.0,50113062,2789,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
60,504749,1,3,28.0,50113062,2789,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
61,504749,1,3,29.0,50113062,2789,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
62,504749,1,3,30.0,50113062,2789,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
63,504749,1,3,31.0,50113062,2789,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
64,504749,1,3,32.0,50113062,2789,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
65,504749,1,3,33.0,50113062,2789,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
66,504749,1,3,34.0,50113062,2789,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
67,504749,1,3,35.0,50113062,2789,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
68,504749,1,3,36.0,50113062,2789,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
69,504749,1,3,37.0,50113062,2789,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
70,504749,1,3,38.0,50113062,2789,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
71,504749,1,3,39.0,50113062,2789,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
72,504749,1,3,40.0,50113062,2789,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
73,504749,1,3,41.0,50113062,2789,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
74,504749,1,3,42.0,50113062,2789,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
75,504749,1,3,43.0,50113062,2789,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
76,504749,1,3,44.0,50113062,2789,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
77,504749,1,3,45.0,50113062,2789,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
78,504749,1,3,46.0,50113062,2789,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
79,504749,1,3,47.0,50113062,2789,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
80,504749,1,3,48.0,50113062,2789,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
81,504749,1,3,49.0,50113062,2789,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
82,504749,1,3,50.0,50113062,2789,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
83,504749,1,3,51.0,50113062,2789,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
84,504749,1,3,52.0,50113062,2789,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
85,504749,1,3,53.0,50113062,2789,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
86,504749,1,3,54.0,50113062,2789,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
87,504749,1,3,55.0,50113062,2789,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
88,504749,1,3,56.0,50113062,2789,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
89,504749,1,3,57.0,50113062,2789,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
90,504749,1,3,58.0,50113062,2789,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
91,504749,1,3,59.0,50113062,2789,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
92,504749,1,3,60.0,50113062,2789,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
93,504749,1,3,61.0,50113062,2789,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
94,504832,1,1,,50113062,2789,Inactive,,,,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
95,504834,1,1,,50113062,2789,Inactive,,,,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
96,504847,1,1,,50113062,2789,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
97,504865,1,1,,50113062,2789,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
98,588211,2,3,,103266846,2789,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans",Other,20014752.0,
99,588212,2,3,,103266846,2789,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents",Other,20014752.0,
100,588213,2,3,,103266846,2789,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents",Other,20014752.0,
101,588579,1,1,,50113062,2789,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
102,588834,2,1,,144206161,2789,Inactive,325651834.0,3757.0,,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
103,602332,1,1,,50113062,2789,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
104,624030,1,2,,50113062,2789,Inactive,160794.0,,,Potency,Biochemical firefly luciferase enzyme assay for NPC,Confirmatory,,
105,624031,1,2,,50113062,2789,Inactive,,,,Potency,S16 Schwann cell viability assay (CellTiter-Glo assay),Confirmatory,,
106,624032,1,2,,50113062,2789,Inactive,8393992.0,24660.0,,Potency,S16 Schwann cell PMP22 intronic element firefly luciferase assay,Confirmatory,,
107,624044,1,2,,50113062,2789,Inconclusive,8393992.0,24660.0,,Potency,S16 Schwann cell PMP22 intronic element beta-lactamase assay,Confirmatory,,
108,624170,1,1,,50113062,2789,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
109,624172,1,1,,50113062,2789,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
110,624173,1,3,,50113062,2789,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
111,624296,1,1,,50113062,2789,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
112,624297,1,1,,50113062,2789,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
113,651631,4,1,,144206161,2789,Inactive,269849759.0,7157.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
114,651632,4,1,,144206161,2789,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
115,651633,4,1,,144206161,2789,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
116,651634,4,1,,144206161,2789,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
117,652048,1,2,,144206161,2789,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
118,652051,1,1,,144206161,2789,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
119,686978,1,1,,144206161,2789,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
120,686979,1,1,,144206161,2789,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
121,720516,2,1,,144206161,2789,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
122,720532,1,1,,144206161,2789,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
123,720533,1,1,,144206161,2789,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
124,720552,2,1,,144206161,2789,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
125,720634,2,1,,144206161,2789,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
126,720635,2,1,,144206161,2789,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
127,720637,2,1,,144206161,2789,Inactive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
128,720674,2,2,,144206161,2789,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
129,720675,2,2,,144206161,2789,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
130,720678,2,1,,144206161,2789,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
131,720679,2,1,,144206161,2789,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
132,720680,2,1,,144206161,2789,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
133,720681,2,1,,144206161,2789,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
134,720682,2,1,,144206161,2789,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
135,720683,2,1,,144206161,2789,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
136,720684,2,1,,144206161,2789,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
137,720685,2,1,,144206161,2789,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
138,720686,2,1,,144206161,2789,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
139,720687,2,2,,144206161,2789,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
140,720691,4,1,,144206161,2789,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
141,720692,3,1,,144206161,2789,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
142,720693,3,1,,144206161,2789,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
143,720719,2,1,,144206161,2789,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
144,720725,2,1,,144206161,2789,Inactive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
145,727832,1,3,,103266846,2789,Unspecified,,,,,Antiepileptic activity in Wistar rat assessed as GABA level in cerebellum per 100 mg at 30 mg/kg ip after 2 hrs (Rvb = 23.48+/- 2.48 ug),Other,23265873.0,
146,727834,1,3,,103266846,2789,Unspecified,,,,,Antiepileptic activity in Wistar rat assessed as GABA level in medulla oblangata per 100 mg at 30 mg/kg ip after 2 hrs (Rvb = 31.86 +/- 4.65 ug),Other,23265873.0,
147,727836,1,3,,103266846,2789,Unspecified,,,,,Antiepileptic activity in Wistar rat assessed as GABA level in midbrain per 100 mg at 30 mg/kg ip after 2 hrs (Rvb = 35.42 +/- 2.14 ug),Other,23265873.0,
148,742652,2,2,,103266846,2789,Active,120773.0,2562.0,,,GABA-A receptor; anion channel positive allosteric modulator,Other,11530681.0,
149,742652,2,2,,103266846,2789,Active,399519.0,2558.0,,,GABA-A receptor; anion channel positive allosteric modulator,Other,11530681.0,
150,742652,2,2,,103266846,2789,Active,462149.0,2556.0,,,GABA-A receptor; anion channel positive allosteric modulator,Other,11530681.0,
151,742652,2,2,,103266846,2789,Active,6016089.0,2568.0,,,GABA-A receptor; anion channel positive allosteric modulator,Other,11530681.0,
152,742652,2,2,,103266846,2789,Active,13124728.0,2564.0,,,GABA-A receptor; anion channel positive allosteric modulator,Other,11530681.0,
153,742652,2,2,,103266846,2789,Active,13959382.0,55879.0,,,GABA-A receptor; anion channel positive allosteric modulator,Other,11530681.0,
154,742652,2,2,,103266846,2789,Active,13959689.0,2567.0,,,GABA-A receptor; anion channel positive allosteric modulator,Other,11530681.0,
155,742652,2,2,,103266846,2789,Active,23831128.0,2560.0,,,GABA-A receptor; anion channel positive allosteric modulator,Other,11530681.0,
156,742652,2,2,,103266846,2789,Active,27808653.0,2554.0,,,GABA-A receptor; anion channel positive allosteric modulator,Other,11530681.0,
157,742652,2,2,,103266846,2789,Active,59802571.0,2563.0,,,GABA-A receptor; anion channel positive allosteric modulator,Other,11530681.0,
158,742652,2,2,,103266846,2789,Active,116242488.0,2566.0,,,GABA-A receptor; anion channel positive allosteric modulator,Other,11530681.0,
159,742652,2,2,,103266846,2789,Active,126302547.0,2555.0,,,GABA-A receptor; anion channel positive allosteric modulator,Other,11530681.0,
160,742652,2,2,,103266846,2789,Active,126302548.0,2559.0,,,GABA-A receptor; anion channel positive allosteric modulator,Other,11530681.0,
161,742652,2,2,,103266846,2789,Active,206729865.0,2557.0,,,GABA-A receptor; anion channel positive allosteric modulator,Other,11530681.0,
162,742652,2,2,,103266846,2789,Active,209572630.0,2565.0,,,GABA-A receptor; anion channel positive allosteric modulator,Other,11530681.0,
163,742652,2,2,,103266846,2789,Active,292495010.0,2561.0,,,GABA-A receptor; anion channel positive allosteric modulator,Other,11530681.0,
164,743012,3,1,,144206161,2789,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
165,743014,3,1,,144206161,2789,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
166,743015,3,1,,144206161,2789,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
167,743033,3,1,,144206161,2789,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
168,743035,2,1,,144206161,2789,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
169,743036,2,1,,144206161,2789,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
170,743040,3,1,,144206161,2789,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
171,743041,3,1,,144206161,2789,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
172,743042,3,1,,144206161,2789,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
173,743053,2,1,,144206161,2789,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
174,743054,2,1,,144206161,2789,Inactive,124375976.0,367.0,,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
175,743063,2,1,,144206161,2789,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
176,743064,3,1,,144206161,2789,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
177,743065,3,1,,144206161,2789,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
178,743066,3,1,,144206161,2789,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
179,743067,2,1,,144206161,2789,Inactive,399498506.0,24831.0,,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
180,743069,2,1,,144206161,2789,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
181,743074,2,1,,144206161,2789,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
182,743075,2,1,,144206161,2789,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
183,743077,2,1,,144206161,2789,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
184,743078,2,1,,144206161,2789,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
185,743079,3,1,,144206161,2789,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
186,743080,3,1,,144206161,2789,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
187,743081,3,1,,144206161,2789,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
188,743083,3,1,,144206161,2789,Inactive,119597822.0,1588.0,11.8832,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
189,743084,3,1,,144206161,2789,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
190,743085,3,1,,144206161,2789,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
191,743086,3,1,,144206161,2789,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
192,743091,2,1,,144206161,2789,Inactive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
193,743094,3,1,,144206161,2789,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
194,743122,2,1,,144206161,2789,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
195,743139,2,1,,144206161,2789,Inconclusive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
196,743140,2,1,,144206161,2789,Inactive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
197,743244,1,1,,144206161,2789,Inactive,,,,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
198,1065309,1,1,,103266846,2789,Unspecified,,,,,"Anticonvulsant activity in Wistar rat assessed as inhibition of GABA-induced seizures measuring minimum GABA level per 100 mg whole brain required for 50 % inhibition at 30 mg/kg, po for 7 days (Rvb = 51.5 +/- 2.60 ug/100 mg brain)",Other,23831504.0,
199,1065310,1,1,,103266846,2789,Unspecified,,,,,"Anticonvulsant activity in Wistar rat assessed as inhibition of GABA-induced seizures measuring minimum GABA level per 100 mg whole brain required for 50 % inhibition at 30 mg/kg, ip as single dose measured after 2 hrs (Rvb = 46.4 +/- 5.50 ug/100 mg brain)",Other,23831504.0,
200,1079931,1,1,,103266846,2789,Unspecified,,,,,"Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]",Other,15646539.0,
201,1079932,1,1,,103266846,2789,Unspecified,,,,,"Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]",Other,15646539.0,
202,1079933,1,1,,103266846,2789,Unspecified,,,,,"Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is number of references indexed. [column 'AIGUE' in source]",Other,15646539.0,
203,1079934,1,1,,103266846,2789,Unspecified,,,,,"Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]",Other,15646539.0,
204,1079935,1,1,,103266846,2789,Unspecified,,,,,"Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]",Other,15646539.0,
205,1079936,1,1,,103266846,2789,Unspecified,,,,,"Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]",Other,15646539.0,
206,1079937,1,1,,103266846,2789,Unspecified,,,,,"Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]",Other,15646539.0,
207,1079938,1,1,,103266846,2789,Unspecified,,,,,"Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]",Other,15646539.0,
208,1079939,1,1,,103266846,2789,Unspecified,,,,,"Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]",Other,15646539.0,
209,1079940,1,1,,103266846,2789,Unspecified,,,,,"Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]",Other,15646539.0,
210,1079941,1,1,,103266846,2789,Unspecified,,,,,"Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]",Other,15646539.0,
211,1079942,1,1,,103266846,2789,Unspecified,,,,,"Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]",Other,15646539.0,
212,1079943,1,1,,103266846,2789,Unspecified,,,,,"Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]",Other,15646539.0,
213,1079944,1,1,,103266846,2789,Unspecified,,,,,"Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]",Other,15646539.0,
214,1079945,1,1,,103266846,2789,Unspecified,,,,,Animal toxicity known. [column 'TOXIC' in source],Other,15646539.0,
215,1079946,1,1,,103266846,2789,Unspecified,,,,,Presence of at least one case with successful reintroduction. [column 'REINT' in source],Other,15646539.0,
216,1079947,1,1,,103266846,2789,Unspecified,,,,,Comments (NB not yet translated). [column 'COMMENTAIRES' in source],Other,15646539.0,
217,1079948,1,1,,103266846,2789,Unspecified,,,,,"Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]",Other,15646539.0,
218,1079949,1,1,,103266846,2789,Unspecified,,,,,Proposed mechanism(s) of liver damage. [column 'MEC' in source],Other,15646539.0,
219,1097336,1,3,,103266846,2789,Unspecified,,,,,Drug level in Homo sapiens (human) whole blood assessed as retention time by UPLC-TOF-MS analysis,Other,,
220,1117301,1,2,,144206161,2789,Inactive,,,28.1838,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 1 blue channel",Confirmatory,,
221,1117302,1,2,,144206161,2789,Inactive,,,2.5119,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen1 green channel",Confirmatory,,
222,1117303,1,2,,144206161,2789,Inactive,,,22.39,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 1 ratio channel",Confirmatory,,
223,1117311,1,1,,144206161,2789,Inactive,,,28.1838,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, blue channel",Confirmatory,,
224,1117315,1,1,,144206161,2789,Inactive,,,2.51189,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, green channel",Confirmatory,,
225,1117318,1,1,,144206161,2789,Inactive,,,22.3872,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, ratio channel",Confirmatory,,
226,1143184,1,1,,103266846,2789,Unspecified,,,,,"Increase in GABA level in Wistar rat whole brain at 30 mg/kg, po for 7 days measured at 4 hrs after last drug dose per 100 mg of tissue (Rvb = 49.2 +/- 3.01 ug)",Other,24813879.0,
227,1143187,1,1,,103266846,2789,Unspecified,,,,,"Increase in GABA level in Wistar rat whole brain at 30 mg/kg, po after 2 hrs measured per 100 mg of tissue (Rvb = 46.8 +/- 6.03 ug)",Other,24813879.0,
228,1159620,1,1,,103266846,2789,Active,,,,,Summary of drug indications.,Other,,
229,1259344,1,1,,144206161,2789,Inactive,,,,Potency,qHTS assay to identify small molecule phospholipidosis (PLD) inducers,Confirmatory,,
230,1259355,1,1,,144206161,2789,Inactive,,,,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-1,Confirmatory,,
231,1259356,1,1,,144206161,2789,Inactive,,,,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-2,Confirmatory,,
232,1259407,1,1,,363905456,2789,Unspecified,,,,,CCRIS mutagenicity studies,Other,,
233,1259416,1,2,,340079736,2789,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
234,1259421,1,1,,340079736,2789,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
